Citi analyst David Lebowitz raised the firm’s price target on Cytokinetics (CYTK) to $84 from $77 and keeps a Buy rating on the shares. The firm says the company’s Phase MAPLE trial data showed aficamten brought significant improvement in exercise capacity versus metoprolol when treating obstructive hypertrophic cardiomyopathy. It believes the result exceeded expectations materially and should rally the shares up to 20% in the near-term.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Buy Rating for Cytokinetics: Aficamten Shows Promising Results in Hypertrophic Cardiomyopathy Trials
- Cytokinetics’ Aficamten Poised to Transform Hypertrophic Cardiomyopathy Treatment Landscape Following Promising Phase 3 Results
- Cytokinetics presents additional data from MAPLE-HCM study
- Cytokinetics announces primary results from MAPLE-HCM trial
- Cytokinetics Stock: Hold Rating Amid Competitive Pressures and Uncertain Commercial Outlook